Palantir Fights Trademark Clash as U.S. Revenues Surge
Sep/25/2025
On September 24, Palantir Technologies lodged a U.S. opposition against EnChannel Medical Guangzhou’s attempt to register PALANTIR for cardiovascular devices ranging from pacemakers to ECG recorders, arguing its proximity to the firm’s own marks such as Palantir Foundry and Palantir Edge AI. The dispute underscores the data analytics company’s determination to guard its brand even beyond its usual software sphere. Palantir, best known for its defense and intelligence work, reported $2.9 billion in global revenue in 2024, with two-thirds generated in the United States and more than half tied to government contracts. Its technology, already entrenched in military, healthcare, and immigration systems, has drawn both billion-dollar Pentagon awards and controversy over its role in surveillance and battlefield targeting. The opposition filing comes as Palantir deepens its entanglement with governments worldwide, its fortunes rising alongside the geopolitical demand for data-driven security and intelligence tools. The following chart shows Palantir Technologies’ annual revenue by segment between fiscal year 2020 and 2024, underscoring the company’s growing dependence on U.S. government contracts as the core of its business model.
